# Summit Therapeutics Inc.

Summary updated: 2026-10-02T12:42:50.568849Z
Canonical: https://finbar.com/research/companies/summit-therapeutics-inc

## Overview

Summit Therapeutics Inc. is a Miami-headquartered biopharmaceutical company focused on developing medicines for serious unmet medical needs, with oncology as its defining area of research. Its stated mission emphasizes improving and extending lives through the development of therapies for patients with serious conditions. [1](https://app.finbar.com/go?id=P26035904)[2](https://app.finbar.com/go?id=P142658204)[3](https://smmttx.com/company/mission-statement/default.aspx)

Its lead candidate is ivonescimab, an investigational bispecific antibody designed to combine PD-1 blockade with anti-VEGF activity. The company’s clinical pipeline includes Phase III studies in non-small cell lung cancer and colorectal cancer. Summit holds licensed rights to ivonescimab in the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa. [4](https://app.finbar.com/go?id=P108359396)[5](https://app.finbar.com/go?id=P34226859)[6](https://app.finbar.com/go?id=P46078506)[7](https://app.finbar.com/go?id=P39595094)[8](https://app.finbar.com/go?id=P111692077)[9](https://app.finbar.com/go?id=P95425847)

Summit reported no revenue in FY2025 or the first half of 2026, reflecting its development-stage business. Its reviewed filings do not state employee headcount; a secondary company-data source estimates 265 employees at December 31, 2025. [10](https://app.finbar.com/go?id=T13287293)[11](https://app.finbar.com/go?id=T16310835)[12](https://stockanalysis.com/stocks/smmt/employees/)
[1](https://app.finbar.com/go?id=P26035904)[2](https://app.finbar.com/go?id=P142658204)[3](https://smmttx.com/company/mission-statement/default.aspx)[4](https://app.finbar.com/go?id=P108359396)[5](https://app.finbar.com/go?id=P34226859)[6](https://app.finbar.com/go?id=P46078506)[7](https://app.finbar.com/go?id=P39595094)[8](https://app.finbar.com/go?id=P111692077)[9](https://app.finbar.com/go?id=P95425847)[10](https://app.finbar.com/go?id=T13287293)[11](https://app.finbar.com/go?id=T16310835)[12](https://stockanalysis.com/stocks/smmt/employees/)[3](https://smmttx.com/company/mission-statement/default.aspx)[12](https://stockanalysis.com/stocks/smmt/employees/)

## Products & services

Summit Therapeutics’ principal product candidate is ivonescimab, an investigational bispecific antibody licensed from Akeso. It targets both PD-1, blocking its interaction with PD-L1 and PD-L2, and VEGF-A, blocking its interaction with VEGF receptors. The antibody’s Tetrabody design is intended to support cooperative binding, with VEGF binding increasing PD-1 affinity. Summit’s licensed territories include the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa. [4](https://app.finbar.com/go?id=P108359396)[13](https://app.finbar.com/go?id=P33629366)

Summit is developing ivonescimab in combination with chemotherapy for advanced or metastatic EGFR-mutated non-small-cell lung cancer after a third-generation EGFR tyrosine-kinase inhibitor, first-line metastatic squamous and non-squamous non-small-cell lung cancer, and first-line unresectable metastatic colorectal cancer; it is also studying ivonescimab alone in first-line metastatic non-small-cell lung cancer with high PD-L1 expression. [6](https://app.finbar.com/go?id=P46078506)[7](https://app.finbar.com/go?id=P39595094)[8](https://app.finbar.com/go?id=P111692077)[9](https://app.finbar.com/go?id=P95425847) Akeso separately develops ivonescimab in other tumors; a partner-led study is evaluating it alone or with ligufalimab, Akeso’s investigational anti-CD47 antibody, in recurrent or metastatic PD-L1-positive head-and-neck squamous cell carcinoma. [14](https://app.finbar.com/go?id=P92215528)[15](https://app.finbar.com/go?id=P142658309)

Summit’s filings describe drug development rather than separately offered services: development, clinical trials and clinical-material manufacturing involve external vendors. The FY2025 filing states that Summit had not yet developed a marketed drug, and does not report product revenue or a product share of performance. [16](https://app.finbar.com/go?id=P77070964)[17](https://app.finbar.com/go?id=P79324843)[18](https://app.finbar.com/go?id=P65088320)
[4](https://app.finbar.com/go?id=P108359396)[13](https://app.finbar.com/go?id=P33629366)[6](https://app.finbar.com/go?id=P46078506)[7](https://app.finbar.com/go?id=P39595094)[8](https://app.finbar.com/go?id=P111692077)[9](https://app.finbar.com/go?id=P95425847)[14](https://app.finbar.com/go?id=P92215528)[15](https://app.finbar.com/go?id=P142658309)[16](https://app.finbar.com/go?id=P77070964)[17](https://app.finbar.com/go?id=P79324843)[18](https://app.finbar.com/go?id=P65088320)

## Geographic presence

Summit Therapeutics is headquartered in Miami, Florida, and has offices in Princeton, New Jersey, and Palo Alto, California. Its filings describe expanded Princeton office space in 2026; they do not provide employee counts by location. [2](https://app.finbar.com/go?id=P142658204)[19](https://app.finbar.com/go?id=P142658227)[20](https://app.finbar.com/go?id=P87289781)

Its licensed territory for ivonescimab includes the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa; Akeso retained rights outside that territory. [21](https://app.finbar.com/go?id=P45554267)[22](https://app.finbar.com/go?id=P142658109) Summit’s clinical studies have included or are planned across North America, Europe, and China, with one planned study also allowing for possible U.S. participation. [23](https://app.finbar.com/go?id=P142658284)[24](https://app.finbar.com/go?id=P142658297)[15](https://app.finbar.com/go?id=P142658309)[25](https://app.finbar.com/go?id=P142658305) The latest annual reporting year identified is 2025, with a Q2 2026 filing also available; the reviewed filings do not disclose revenue by region or geographic percentages. [26](https://app.finbar.com/go?id=P142658097)
[2](https://app.finbar.com/go?id=P142658204)[19](https://app.finbar.com/go?id=P142658227)[20](https://app.finbar.com/go?id=P87289781)[21](https://app.finbar.com/go?id=P45554267)[22](https://app.finbar.com/go?id=P142658109)[23](https://app.finbar.com/go?id=P142658284)[24](https://app.finbar.com/go?id=P142658297)[15](https://app.finbar.com/go?id=P142658309)[25](https://app.finbar.com/go?id=P142658305)[26](https://app.finbar.com/go?id=P142658097)

## Business segments

Summit Therapeutics reports one operating and reportable segment. Its operations are managed on a consolidated basis, with the segment focused on developing ivonescimab and other future activities; clinical-trial costs, including oncology-related costs, are among its principal expenses. [26](https://app.finbar.com/go?id=P142658097)[27](https://app.finbar.com/go?id=P142658070)[28](https://app.finbar.com/go?id=T16310839)

The single segment encompasses all reported operations, but the company does not disclose a separate segment revenue, asset, or operating-contribution percentage breakdown. Its Q2 2026 filing also states that substantially all long-lived assets are located in the United States; this is a geographic disclosure, not a separate business segment. [26](https://app.finbar.com/go?id=P142658097)[29](https://app.finbar.com/go?id=P142658100)
[26](https://app.finbar.com/go?id=P142658097)[27](https://app.finbar.com/go?id=P142658070)[28](https://app.finbar.com/go?id=T16310839)[29](https://app.finbar.com/go?id=P142658100)

## Company history

Summit’s corporate lineage dates to its incorporation in 2004 as VASTox plc. It became Summit Corporation plc in 2007 and Summit Therapeutics plc in 2015, the year it completed a U.S. IPO and began trading on Nasdaq. [30](https://find-and-update.company-information.service.gov.uk/company/05197494)[31](https://www.sec.gov/Archives/edgar/data/1599298/000119312515028037/d822352df1.htm) In the 2010s, the company focused on antibiotic development, including ridinilazole for C. difficile infection; in 2017, it entered a development-support agreement with BARDA. [32](https://www.sec.gov/Archives/edgar/data/1599298/000119312517375529/d503630dex991.htm)

In 2020, Summit reorganized as a Delaware corporation, with Summit Therapeutics Inc. becoming the successor issuer and parent of the UK group. [33](https://app.finbar.com/go?id=P175975269)[34](https://app.finbar.com/go?id=P175976569) After Robert W. Duggan became CEO in April 2020, the company shifted away from internal development of ridinilazole and in December 2022 licensed ivonescimab from Akeso for specified markets outside China and other retained territories. [35](https://smmttx.com/company/leadership/default.aspx)[36](https://www.sec.gov/Archives/edgar/data/1599298/000159929825000048/R15.htm)[37](https://app.finbar.com/go?id=P54459567)[21](https://app.finbar.com/go?id=P45554267) Ivonescimab subsequently became the company’s central development program; China approved it for NSCLC indications in 2024 and 2025. [14](https://app.finbar.com/go?id=P92215528)
[33](https://app.finbar.com/go?id=P175975269)[34](https://app.finbar.com/go?id=P175976569)[37](https://app.finbar.com/go?id=P54459567)[21](https://app.finbar.com/go?id=P45554267)[14](https://app.finbar.com/go?id=P92215528)[30](https://find-and-update.company-information.service.gov.uk/company/05197494)[31](https://www.sec.gov/Archives/edgar/data/1599298/000119312515028037/d822352df1.htm)[32](https://www.sec.gov/Archives/edgar/data/1599298/000119312517375529/d503630dex991.htm)[35](https://smmttx.com/company/leadership/default.aspx)[36](https://www.sec.gov/Archives/edgar/data/1599298/000159929825000048/R15.htm)

## Sources

1. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P26035904)
2. [Summit Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P142658204)
3. [smmttx.com](https://smmttx.com/company/mission-statement/default.aspx)
4. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P108359396)
5. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P34226859)
6. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P46078506)
7. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P39595094)
8. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P111692077)
9. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P95425847)
10. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T13287293)
11. [Summit Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16310835)
12. [stockanalysis.com](https://stockanalysis.com/stocks/smmt/employees/)
13. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P33629366)
14. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P92215528)
15. [Summit Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P142658309)
16. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P77070964)
17. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P79324843)
18. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P65088320)
19. [Summit Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P142658227)
20. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P87289781)
21. [Summit Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P45554267)
22. [Summit Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P142658109)
23. [Summit Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P142658284)
24. [Summit Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P142658297)
25. [Summit Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P142658305)
26. [Summit Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P142658097)
27. [Summit Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P142658070)
28. [Summit Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16310839)
29. [Summit Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P142658100)
30. [find-and-update.company-information.service.gov.uk](https://find-and-update.company-information.service.gov.uk/company/05197494)
31. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1599298/000119312515028037/d822352df1.htm)
32. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1599298/000119312517375529/d503630dex991.htm)
33. [Summit Therapeutics Inc. — Full financial report (2020 Y)](https://app.finbar.com/go?id=P175975269)
34. [Summit Therapeutics Inc. — Full financial report (2020 Y)](https://app.finbar.com/go?id=P175976569)
35. [smmttx.com](https://smmttx.com/company/leadership/default.aspx)
36. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1599298/000159929825000048/R15.htm)
37. [Summit Therapeutics Inc. — Full financial report (2024 Y)](https://app.finbar.com/go?id=P54459567)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.